Twist Bioscience Begins Shipping Commercial Product from Synthetic DNA Manufacturing Factory of the Future

Date released January 26, 2023 /

110,000 square-foot state-of-the-art facility supports significantly expanded product manufacturing capacity and will enable new product introductions

 

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the shipments of the first products from its second manufacturing site, the Factory of the Future, in Wilsonville, Oregon.

“These initial shipments of Twist Oligo Pools and Gene Fragments are the start of what we believe will be significant capacity and revenue growth enabled by the Factory of the Future,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “As we continue to expand initial manufacturing from this new facility, we will add genes, with the same rapid turnaround time as that of South San Francisco. We are also working longer term toward new product introductions supported by the additional capacity that will allow us to tap into new markets, including the launch of fast genes, which we expect will offer significantly faster turnaround time for manufacturing genes.”

The Factory of the Future is a 110,000 square-foot facility in Wilsonville, Oregon. The size of the site allows for an assembly-line style manufacturing approach, where each machine is used for a singular purpose. The Factory of the Future is expected to double Twist’s manufacturing capacity. Twist also has access to an additional 100,000 square-feet to support future expansion.

Current turnaround times for Twist Bioscience products:

  • Clonal genes: starting at 10 business days
  • Gene fragments: starting at 5 business days
  • Oligo pools: starting at 5 business days
Share to LinkedIn
Share to Twitter